|
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis
|
03 June 2010 |
|
Amgen's First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion
|
23 April 2010 |
|
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
|
24 February 2010 |
|
Denosumab Trial met Primary and all Secondary Endpoints
|
10 February 2010 |
|
Amgen Donates $2 Million, Establishes Earthquake Relief Program
|
15 January 2010 |
|
Array BioPharma and Amgen Partner in Type 2 Diabetes
|
16 December 2009 |
|
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
|
05 December 2009 |
|
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
|
06 November 2009 |
|
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent
|
22 October 2009 |
|
Denosumab Demonstrates Superiority Over Zometa(R)
|
22 September 2009 |
|
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product
|
16 September 2009 |
|
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy
|
26 August 2009 |
|
Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab)
|
18 August 2009 |
|
Studies Highlight Potential New Option in the Treatment of Bone Loss
|
12 August 2009 |
|
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
|
05 August 2009 |
|
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
|
28 July 2009 |
|
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial
|
10 July 2009 |
|
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure
|
08 June 2009 |
|
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
|
24 April 2009 |
|
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
|
19 February 2009 |